Selection criteria for liver transplantation in patients with hepatocellular carcinoma. Eastern and western experiences, and perspectives for the future.
Schielke, Astrid Anita; MEURISSE, Nicolas; LAMPROYE, Anneet al.
2019 • In Acta Gastro-Enterologica Belgica, 82 (2), p. 314-318
Milan criteria; biomarkers; hepatocellular carcinoma; microvascular invasion; organ transplantation; transplantation
Abstract :
[en] Ever since the initial description of the Milan criteria, used for selecting patients with hepatocellular carcinoma (HCC) for liver transplantation (LT), there has been a clear need to go further than solely morphological criteria. Tumours exceeding the Milan criteria, but presenting favourable biological behaviour, might still allow for comparable overall- and disease-free survivals after LT. As it is well established that the presence of microvascular invasion is a major factor that influences HCC recurrence after LT, several serum and tissue biomarkers in addition to imaging studies are attracting wider attention as more refined tools for selecting HCC patients for LT. A thorough review of the recent literature on the subject was conducted. In the future a combination of systemic inflammation markers, biomarkers and morphological criteria may be key to more accurate prediction of HCC recurrence after LT. This may allow LT in patients whose HCC tumours exceed the Milan criteria but have favourable biological behaviour. Further prospective studies are required in order to improve patient selection for transplantation in HCC and these could help a move towards more transparent and improved management.
Disciplines :
Gastroenterology & hepatology Surgery
Author, co-author :
Schielke, Astrid Anita ; Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
MEURISSE, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
LAMPROYE, Anne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
Honoré, Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgicale abdominale
Delwaide, Jean ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Hustinx, Roland ; Université de Liège - ULiège > Département des sciences cliniques > Médecine nucléaire
DETRY, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Département de chirurgie > Chirurgie abdo, sénologique, endocrine et de transplantation
Language :
English
Title :
Selection criteria for liver transplantation in patients with hepatocellular carcinoma. Eastern and western experiences, and perspectives for the future.
BOSCH F., RIBES J., DIAZ M., CLERIES R. Primary liver cancer: worldwide incidence and trends. Gastroenterology, 2004, 127 (Suppl 1): S5-S16.
PARKIN D., BRAY F., FERLAY J., PISANI P. Global cancer statistics, 2002. CA Cancer J Clin., 2005, 55: 74-108.
JEMAL A., CENTER M., DE SANTIS C., Ward E. Global patterns of cancer incidence and mortality rates and trends. Canc Epidemiol Biomarkers Prev., 2010, 19: 1893-1907.
KAKDODKAR R, SOIN A. Liver Transplantation for HCC: A Review. Indian J Surg., 2012, 74: 100-117.
MAZZAFERRO V., REGALIA E., DOCI R., ANDREOLA S., PULVERENTI A., BOZZETTI F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med., 1996, 334: 693-699.
YAO F., FERREL L., BASS N., WATSON J., BACCHETTI P., VENOOK A., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33(6): 1394-1403.
HERRERO J., SANGRO B., QUIROGA J., PARDO F., HERRAIZ M., CIENFUEGOS J., et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl., 2001, 7: 631-6.
ROAYAIE S., FRISCHER J., EMRE S., FISHBEIN T., SHEINER P., SUNG M., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinoma larger than 5 centimeters. Ann Surg., 2002, 235: 533-9.
KNETEMANN N., OBERHOLZER J., AL SAGHIER M., MEEBERG G., BLITZ M., MA M., et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplant., 2004, 10: 1301-11.
ONACA N., DAVIS G., GOLDSTEIN R., JENNINGS L., KLINTMALM G. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl., 2007, 13: 391-9.
CILLO U., VITALE A., GRIGOLETTO F., GRINGERI E., D’AMICO F., VALMASONI M. et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant., 2007, 7: 972-81.
GUITEAU J., COTTON R., WASHBURN W., HARPER A., O’MAHONY C., SEBASTIAN A., et al. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant., 2010, 10: 2092-8.
MENON K., HAKEEM A., HEATON N. Review article: liver transplantation for hepatocellular carcinoma-a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther., 2014, 40: 893-902.
MAZZAFERRO V., LLOVET J., MICELI R., BHOORI S., SCHIAVO M., MARIANI L., et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective exploratory analysis. Lancet Oncol., 2009, 10 (1): 35-43.
D’AMICO F., SCHWARTZ M., VITALE A., TABRIZIAN P., ROAYAIE S., THUNG S., et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl., 2009, 15: 1278-1287.
CITORES M., LUCENA J., DE LA FUENTE S., CUERVAS-MONS V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol., 2019, 11: 50-64.
AMADO V., RODRIGUEZ-PREALVAREZ M., FERRIN G., DE LA MATA M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma., 2018, 6: 1-10.
YANG S., SUH K., LEE H., CHO E., CHO J., CHO Y., et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery., 2007; 141: 598-609.
ZHENG S., XU X., WU J., CHEN J., WANG W., ZHANG M., et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Trans-plantation, 2008, 85: 1726-1732.
KIM J., KWON C., JOH J., PARK J., LEE J., KIM G., et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc., 2014, 46: 726-729.
SHIMAMURA T., AKAMATSU N., FUJIYOSHI M., KAWAGUCHI A., MORITA S., KAWASAKI S., et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule-a retrospective study. Transpl Int., 2019, 32: 356-368.
DUVOUX C., ROUDOT-THORAVAL F., DECAENS T., PESSIONE F., BADRAN H., PIARDI T., et al. Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology, 2012, 143: 986-94.e3; quiz e14-5.
CILLO U., GUILIANI T., POLACCO M., HERRERO-MANLY L., CRIVELLARI G., VITALE A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol., 2016, 22(1): 232-252.
TAKADA Y., ITO T., UEDA M., SAKAMOTO S., HAGA H., MAETANI Y., et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis., 2007, 25: 299-302.
SOEJIMA Y.., TAKETOMI A, YOSHIZUMI T., UCHIYAMA H., AISHIMA S., TERASHI T., et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation, 2007, 83: 893-899.
TODO S., FURUKAWA H., TADA M. Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl., 2007, 13: S48-S54 .
YANG K., LEE T., CHOI B., PARK Y., RYU J., JOO D., et al. Development and Applicability of the AP 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc., 2016, 48: 3317-3322.
KIM S., MOON D., KIM W., KANG W., KWON J., JWA E., et al. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr., 2016, 5: 461-469.
QI X., LI J., DENG H., LI H., SU C., GUO X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget, 2016, 7: 45283-45301.
XU Z., YE C., LIU L., WU G., ZHAO Z., WANG Y., et al. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. Biomark Med., 2018, 12: 189-199.
ZHAO Y., SI G., ZHU F., HUI J., CAI S., HUANG C., et al. Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget, 2017, 8: 22854-22862.
CHENG J., WANG W., ZHANG Y., LIU X., LI M., WU Z., et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One., 2014, 9: e87011.
YORITA K., TAKAHASHI N., TAKAI H., KATO A., SUZUKI M., ISHIGURO T., et al. Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int., 2011, 31: 120-31.
SHIRAKAWA H., SUZUKI H., SHIMOMURA M., KOJIMA M., GOTOHDA N., TAKAHASHI S., et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci., 2009, 100: 1403-7.
ZHAI B., YAN H., LIU S., CHEN L., WU M., WANG H.. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J Gastroenterol., 2008, 14: 5665-73.
BECKEBAUM S., CHEN X., SOTIROPOULOS G., RADTKE A., DAOUDAKI M., BABA H., et al. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection. Transplant Proc., 2008, 40: 3182-4.
HAUG R. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging., 2017, 61: 292-300. .
CASTILLA-LIEVRE M., FRANCO D., GERVAIS P., KUHNAST B., AGOSTINI H., MARTHEY L., et al. Diagnostic value of combining ¹¹C-choline and18F-FDG PET/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging., 2016, 43: 852-9.
KORNBERG A., KÜPPER B., THRUM K., KATENKAMP K., STEENBECK J., SAPPLER A., et al. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc., 2009, 41: 2561-3.
KORNBERG A., WITT U., SCHERNHAMMER M., KORNBERG J., CEYHAN G., MUELLER K., et al. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep., 2017, 7: 14176.
DETRY O., GOVAERTS L., DEROOVER A., VANDERMEULEN M., MEURISSE N., MALENGA S., et al. Prognostic value of (18)F-FDG PET/ CT in liver transplantation for hepatocarcinoma. World J Gastroenterol 2015, 21: 3049-3054.
DETRY O., VANDEYNSE D., VANVLIERBERGHE H-, PIRENNE J. Organ procurement and transplantation in Belgium. Transplantation, 2017, 101(9): 1953-1955.
ADLER M, DE PAUW F, VEREERSTRAETEN P, FANCELLO A, LERUT J, STARKEL P, et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl., 2008, 14: 526-533.